La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Madrigal Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Bill Sibold

Directeur général

US$32.9m

Rémunération totale

Pourcentage du salaire du PDG	0.8%
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	8yrs

Mises à jour récentes de la gestion

Recent updates

Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher

Aug 09

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Feb 07

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Dec 20

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Aug 05

Madrigal: Buy And Hoard Before Q4 Data Readout

Aug 04

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Jul 08

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 11

Madrigal: NASH Data In Q4 Is The Key

Apr 19

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Feb 24

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Jan 31

Madrigal: Powerful Catalyst Approaching

Jan 09

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Nov 08

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Jul 26

Madrigal Pharmaceuticals: Leading The NASH Innovation

May 05

Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

Apr 12

We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth

Dec 28

Madrigal Pharma: A Look At The Early MAESTRO Trial Data

Nov 27

Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow

Nov 17

Madrigal Pharmaceuticals EPS misses by $0.40

Nov 05

Analyse de la rémunération des PDG

Comment la rémunération de Bill Sibold a-t-elle évolué par rapport aux bénéfices de Madrigal Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$510m
Mar 31 2024	n/a	n/a	-US$444m
Dec 31 2023	US$33m	US$275k	-US$374m

Rémunération vs marché: La rémunération totale de Bill ($USD 32.87M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 8.39M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Bill avec les performances de l'entreprise.

PDG

Bill Sibold (58 yo)

less than a year

Titularisation

US$32,871,801

Compensation

Mr. William J. Sibold, also known as Bill, serves as Chief Executive Officer, President and Director at Madrigal Pharmaceuticals, Inc. since September 8, 2023. Mr. Sibold joined Madrigal Pharmaceuticals, I...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
William Sibold	CEO, President & Director	less than a year	US$32.87m	pas de données
Rebecca Taub	Founder	12.9yrs	US$6.93m	5.02% $ 279.2m
Carole Huntsman	Chief Commercial Officer	less than a year	US$3.14m	pas de données
Mardi Dier	CFO & Senior VP	less than a year	pas de données	pas de données
Ronald Filippo	Chief Information Officer	less than a year	pas de données	pas de données
Tina Ventura	Chief Investor Relations Officer	less than a year	pas de données	pas de données
Shannon Kelley	Chief Compliance Office & General Counsel	no data	pas de données	pas de données
Clint Wallace	Chief Human Resources Officer	less than a year	pas de données	pas de données
Edward Chiang	Senior Vice President of Clinical & Technical Operations	no data	pas de données	pas de données
Thomas Hare	Senior Vice President of Clinical Management	no data	pas de données	pas de données
Robert Waltermire	Chief Pharmaceutical Development Officer	3yrs	pas de données	0.025% $ 1.4m
Stephen Dodge	Senior Vice President of Global Medical Affairs	2.8yrs	pas de données	pas de données

0.8yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: L'équipe de direction de MDGL n'est pas considérée comme expérimentée (ancienneté moyenne 0.8 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
William Sibold	CEO, President & Director	less than a year	US$32.87m	pas de données
Rebecca Taub	Founder	8.1yrs	US$6.93m	5.02% $ 279.2m
Frederick Craves	Independent Lead Director	8.1yrs	US$65.00k	1.78% $ 98.8m
Kenneth Bate	Independent Director	8.1yrs	US$77.50k	0.0055% $ 307.0k
Julian Baker	Independent Chairman of the Board	1.2yrs	US$33.75k	0.011% $ 614.1k
Paul Friedman	Director	8.1yrs	US$9.80m	4.37% $ 243.0m
Richard Levy	Independent Director	8yrs	US$62.50k	0.047% $ 2.6m
James Daly	Independent Director	5.2yrs	US$57.50k	0.0055% $ 307.0k
Raymond Cheong	Independent Director	1.2yrs	US$27.50k	0.011% $ 614.1k

8.0yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de MDGL sont considérés comme expérimentés (ancienneté moyenne 8 ans).

Madrigal Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Independent Lead Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Recent updates

Consensus revenue estimates increase by 34%, EPS downgraded

Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher

While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Insider exercised options and sold US$513k worth of stock

Senior VP & General Counsel exercised options and sold US$894k worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Price target increased by 7.4% to US$341

Insider exercised options and sold US$1.9m worth of stock

Consensus revenue estimates fall by 92%

Independent Director exercised options and sold US$4.3m worth of stock

Senior VP & General Counsel exercised options and sold US$2.5m worth of stock

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Price target increased to US$164

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Buy And Hoard Before Q4 Data Readout

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal: NASH Data In Q4 Is The Key

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom

Madrigal: Powerful Catalyst Approaching

Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate